Glaxosmithkline Biologicals Sa

Remi Palmantier

Normand Blais

Clement Rioux

Carlota Vinals Y De Bassols

Thierry Coche

Jean-Pol Cassart

Denis Martin

Martine Harvey

Anthony Pilorget

Martine Boyer

Vincent Brichard

Jamila Louahed

The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same.

CASB7439 constructs

Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.

Fusion protein

Compositions and methods for the therapy and diagnosis of cancer, particularly lung, colon, colorectal and breast cancer, are disclosed. Illustrative compositions comprise one or more Cripto tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung, colon, colorectal and breast cancer.

Cripto tumour polypeptide

Growing community of inventors

Rixensart, Belgium

Remi Palmantier